Denali Therapeutics Statistics
Share Statistics
Denali Therapeutics has 145.28M
shares outstanding. The number of shares has increased by 1.83%
in one year.
| Shares Outstanding | 145.28M |
| Shares Change (YoY) | 1.83% |
| Shares Change (QoQ) | 0.9% |
| Owned by Institutions (%) | 75.5% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,268 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 11.74M, so 8.08% of the outstanding
shares have been sold short.
| Short Interest | 11.74M |
| Short % of Shares Out | 8.08% |
| Short % of Float | 9.05% |
| Short Ratio (days to cover) | 8.29 |
Valuation Ratios
The PE ratio is -7.93 and the forward
PE ratio is -5.55.
Denali Therapeutics's PEG ratio is
-0.06.
| PE Ratio | -7.93 |
| Forward PE | -5.55 |
| PS Ratio | 0 |
| Forward PS | 2.4 |
| PB Ratio | 2.73 |
| P/FCF Ratio | -9.22 |
| PEG Ratio | -0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Denali Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.46,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.46 |
| Quick Ratio | 8.46 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.13 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-954,340.86 |
| Employee Count | 443 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 68K |
| Effective Tax Rate | -0.02% |
Stock Price Statistics
The stock price has increased by -32.93% in the
last 52 weeks. The beta is 1.49, so Denali Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | -32.93% |
| 50-Day Moving Average | 14.39 |
| 200-Day Moving Average | 21.9 |
| Relative Strength Index (RSI) | 44.45 |
| Average Volume (20 Days) | 1,445,128 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -487.34M |
| Net Income | -422.77M |
| EBITDA | -414.91M |
| EBIT | -422.7M |
| Earnings Per Share (EPS) | -2.57 |
Full Income StatementBalance Sheet
The company has 174.96M in cash and 48.71M in
debt, giving a net cash position of 126.25M.
| Cash & Cash Equivalents | 174.96M |
| Total Debt | 48.71M |
| Net Cash | 126.25M |
| Retained Earnings | -1.54B |
| Total Assets | 1.27B |
| Working Capital | 786.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -347.69M
and capital expenditures -15.91M, giving a free cash flow of -363.61M.
| Operating Cash Flow | -347.69M |
| Capital Expenditures | -15.91M |
| Free Cash Flow | -363.61M |
| FCF Per Share | -2.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
